Medtronic-Hall prosthesis: valve related XXXX and complications.

@entity1 @entity548 @entity1031 @entity204 @entity884
The purpose of this retrospective study was to assess the clinical performance of the Medtronic-Hall prosthesis based on a review of all valve related complications over a period of nine years. From January 1978 until December 1986, 502 prostheses were implanted in 450 @entity1 . There were 200 aortic valve replacements, 198 mitral valve replacements and 52 double valve replacements. There were 234 associated procedures performed, the most frequent being coronary grafting in 129 @entity1 and tricuspid annuloplasty in 35 @entity1 . The mean age of the @entity1 (230 @entity1 and 220 @entity1 ) was 54.08 +/- 11.7 years. Preoperatively, 92.2% were in NYHA class III or IV. Early mortality was 7.1% and late mortality 16.7%. The follow-up totalled 1733 @entity1 -years (mean 49.8 +/- 31.7 months). Over a period of nine years, the valve related complication rate was 4.4% per @entity1 -year. @entity1031 events occurred in 37 @entity1 (2.1% per patient-year), anticoagulant related @entity548 in 23 @entity1 (1.3% per @entity1 -year), @entity884 in 11 @entity1 (0.6% per @entity1 -year), perivalvular leak in six @entity1 (0.3% per @entity1 -year) and @entity204 and reoperation in 28 @entity1 (1.6% per @entity1 -year). At eight and one-half years, the survival rate was 71.28 +/- 2.7% for the whole group. The actuarial rate of @entity1 free from all valve related complications was 75.92 +/- 2.7%, rate of freedom from @entity1031 was 86.01 +/- 2.4%, freedom from anticoagulant related @entity548 was 92.7 +/- 1.6%, freedom from @entity884 was 97.17 +/- 0.8%, freedom from perivalvular leak was 98.27 +/- 0.7% and freedom from @entity204 and reoperation was 90.70 +/- 1.9%.(ABSTRACT TRUNCATED AT 250 WORDS)
